A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner
The current COVID-19 pandemic has highlighted the urgent need to develop effective therapeutic strategies. We evaluated the in vitro antiviral effect against SARS-CoV-2 of a hepatitis B virus (HBV) hexamer peptide, Poly6, which is capable of eliciting an antiviral effect against human immunodeficien...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/7/1227 |
| _version_ | 1797528844830244864 |
|---|---|
| author | Yu-Min Choi Hyein Jeong Uni Park Nam-Hyuk Cho Bum-Joon Kim |
| author_facet | Yu-Min Choi Hyein Jeong Uni Park Nam-Hyuk Cho Bum-Joon Kim |
| author_sort | Yu-Min Choi |
| collection | DOAJ |
| description | The current COVID-19 pandemic has highlighted the urgent need to develop effective therapeutic strategies. We evaluated the in vitro antiviral effect against SARS-CoV-2 of a hepatitis B virus (HBV) hexamer peptide, Poly6, which is capable of eliciting an antiviral effect against human immunodeficiency virus -1 (HIV-1), as a novel HIV-1 integrase inhibitor, and a strong anticancer immune response in an IFN-I-dependent manner, as a novel potential adjuvant in anticancer immunotherapy. Here, we report that Poly6 exerts an anti-SARS-CoV-2 effect, with an estimated 50% inhibitory concentration of 2.617 µM, in the human bronchial epithelial cell line, Calu-3 but not in Vero-E6 cells, which are deficient in type 1 interferon (IFN-I) signaling. We proved via assays based on mRNA profiles, inhibitors, or blocking antibodies that Poly6 can exert an anti-SARS-CoV-2 effect in an IFN-I-dependent manner. We also found that Poly6 inhibits IL-6 production enhanced by SARS-CoV-2 in infected Calu-3 cells at both the transcription and the translation levels, mediated via IL-10 induction in an IFN-I-dependent manner. These results indicate the feasibility of Poly6 as an IFN-I-inducing COVID-19 drug with potent antiviral and anti-inflammatory activities. |
| first_indexed | 2024-03-10T10:04:09Z |
| format | Article |
| id | doaj.art-fcdad3041165464bb03e5045aa5ac211 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T10:04:09Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-fcdad3041165464bb03e5045aa5ac2112023-11-22T01:42:19ZengMDPI AGViruses1999-49152021-06-01137122710.3390/v13071227A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent MannerYu-Min Choi0Hyein Jeong1Uni Park2Nam-Hyuk Cho3Bum-Joon Kim4Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, KoreaDepartment of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, KoreaThe current COVID-19 pandemic has highlighted the urgent need to develop effective therapeutic strategies. We evaluated the in vitro antiviral effect against SARS-CoV-2 of a hepatitis B virus (HBV) hexamer peptide, Poly6, which is capable of eliciting an antiviral effect against human immunodeficiency virus -1 (HIV-1), as a novel HIV-1 integrase inhibitor, and a strong anticancer immune response in an IFN-I-dependent manner, as a novel potential adjuvant in anticancer immunotherapy. Here, we report that Poly6 exerts an anti-SARS-CoV-2 effect, with an estimated 50% inhibitory concentration of 2.617 µM, in the human bronchial epithelial cell line, Calu-3 but not in Vero-E6 cells, which are deficient in type 1 interferon (IFN-I) signaling. We proved via assays based on mRNA profiles, inhibitors, or blocking antibodies that Poly6 can exert an anti-SARS-CoV-2 effect in an IFN-I-dependent manner. We also found that Poly6 inhibits IL-6 production enhanced by SARS-CoV-2 in infected Calu-3 cells at both the transcription and the translation levels, mediated via IL-10 induction in an IFN-I-dependent manner. These results indicate the feasibility of Poly6 as an IFN-I-inducing COVID-19 drug with potent antiviral and anti-inflammatory activities.https://www.mdpi.com/1999-4915/13/7/1227SARS-CoV-2type I IFN (IFN-I)a hepatitis B virus (HBV)-derived peptidePoly6IL-6 |
| spellingShingle | Yu-Min Choi Hyein Jeong Uni Park Nam-Hyuk Cho Bum-Joon Kim A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner Viruses SARS-CoV-2 type I IFN (IFN-I) a hepatitis B virus (HBV)-derived peptide Poly6 IL-6 |
| title | A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner |
| title_full | A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner |
| title_fullStr | A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner |
| title_full_unstemmed | A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner |
| title_short | A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner |
| title_sort | hepatitis b virus derived peptide can inhibit infection of human lung cells with sars cov 2 in a type 1 interferon dependent manner |
| topic | SARS-CoV-2 type I IFN (IFN-I) a hepatitis B virus (HBV)-derived peptide Poly6 IL-6 |
| url | https://www.mdpi.com/1999-4915/13/7/1227 |
| work_keys_str_mv | AT yuminchoi ahepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT hyeinjeong ahepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT unipark ahepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT namhyukcho ahepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT bumjoonkim ahepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT yuminchoi hepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT hyeinjeong hepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT unipark hepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT namhyukcho hepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner AT bumjoonkim hepatitisbvirusderivedpeptidecaninhibitinfectionofhumanlungcellswithsarscov2inatype1interferondependentmanner |